JS026
/ Shanghai Junshi Bioscience
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 01, 2023
A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19
(clinicaltrials.gov)
- P1 | N=48 | Completed | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease
January 26, 2022
Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants.
(PubMed, Emerg Microbes Infect)
- No abstract available
Combination therapy • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
January 20, 2022
A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19
(clinicaltrials.gov)
- P1; N=48; Active, not recruiting; Sponsor: Shanghai Junshi Bioscience Co., Ltd.; Not yet recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease
1 to 3
Of
3
Go to page
1